Dr. Hao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 Rose Street
Lexington, KY 40536Phone+1 859-323-7507
Education & Training
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2007 - 2010
Atrium Health Navicent The Medical Center/Mercer University School of MedicineResidency, Internal Medicine, 2004 - 2007- OtherClass of 1986
Certifications & Licensure
KY State Medical License 2023 - 2025
GA State Medical License 2009 - 2019- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Lung Cancer With Copanlisib and Durvalumab Start of enrollment: 2021 May 12
Roles: Principal Investigator, Contact, Sponsor-Investigator
- ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer Start of enrollment: 2022 Apr 01
Roles: Contact, Principal Investigator, Sponsor-Investigator
Publications & Presentations
PubMed
- 20 citationsAdjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cells.Zhi-Chun Ding, Tsadik Habtetsion, Yang Cao, Tao Li, Chufeng Liu
Scientific Reports. 2017-09-22 - 12 citationsPhase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancersMartin Gutierrez, Robin Guo, Giuseppe Giaccone, Stephen V. Liu, Zhonglin Hao
Lung Cancer. 2021-10-08 - 140 citationsProtein Nanocage Mediated Fibroblast-Activation Protein Targeted Photoimmunotherapy To Enhance Cytotoxic T Cell Infiltration and Tumor Control.Zipeng Zhen, Wei Tang, Mengzhe Wang, Shiyi Zhou, Hui Wang
Nano Letters. 2017-01-04
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
